Skip to main content

Table 2 Unitary costs (€, 2016) and parameters used in the model

From: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

Parameter Resource consumption Source
Prophylaxis costs
 Pharmaceutical cost
  Palivizumab (Synagis ®) 50 mg per vial (€) 511.66 [34]
  Palivizumab (Synagis ®) 100 mg per vial (€) 849.64 [34]
  Average pharmaceutical cost (EFP/mg) (€) 7.30  
  Average dose (mg/preterm infant) per injection 65.34  
 Administration cost
  Average number of injections 3.88 [28]
  Administration cost per injection (€)- 9.58 [36]
 Hospitalization cost
  Daily cost in paediatric ward (€) 641.06 [36]
  Hospital length of stay (days) 6 Post-hoc analysis FLIP II study [14]
 ICU related costs
  Daily costs in ICU paediatric ward (€) 2,286.28 [36]
  ICU length of stay (days) cost per visit 5 [14]
 Emergency visit prior hospitalization cost
  Daily cost of emergency ward (€) 103.95 [36]
 Annual recurrent wheezing management costs
  Direct cost (€) 749.57 [37]
  Indirect cost (€) 498.62 [37]
  1. EFP: ex-factory price; ICU: intensive care unit